Citations

Showing 10 of 108104 citations.

Radiation Therapy for Brain Metastases: ASCO Guideline Endorsement of ASTRO Guideline
Schiff, David , Messersmith, Hans , Brastianos, Priscilla K. , Brown, Paul D. , Burri, Stuart H., Dunn, Ian F. , Gaspar, Laurie E., Gondi, Vinai , Maués, Julia , Mohile, Nimish, Redjal, Navid , Stevens, Glen , Bent, Martin J. van den , Wallace, H. James , Zadeh, Gelareh , Vogelbaum, Michael A. , Schiff, David , Jordan, Justin T , Maues, Julia , Redjal, Navid , Stevens, Glen , Sulman, Erik P , van den Bent, Martin J , Wallace, H James , Vogelbaum, Michael A , Messersmith, Hans , Jordan, Justin T. , Sulman, Erik P.

Mayo Clinic

Journal of Clinical Oncology | May 13, 2022 | Volume: 40 | Issue: 20 | Pages: 2271-2276

10.1200/jco.22.00333 | PMID 35561283 Get It

PURPOSE American Society of Radiation Oncology (ASTRO) has developed a guideline on appropriate radiation therapy for brain metastases. ASCO has a policy and set of procedures for endorsing clinical practice guidelines that have been developed by other professional organizations. METHODS “Radiation Therapy for Brain Metastases: An ASTRO Clinical Practice Guideline” 2 was reviewed for developmental rigor by methodologists. An ASCO Endorsement Panel subsequently reviewed the content and the recommendations. RESULTS The ASCO Endorsement Panel determined that the recommendations from the ASTRO guideline, published May 6, 2022, are clear, thorough, and based upon the most relevant scientific evidence. ASCO endorses “Radiation Therapy for Brain Metastases: An ASTRO Clinical Practice Guideline.” 2 RECOMMENDATIONS Within the guideline, stereotactic radiosurgery (SRS) is recommended for patients with Eastern Cooperative Oncology Group performance status of 0-2 and up to four intact brain metastases, and conditionally recommended for patients with up to 10 intact brain metastases. The guideline provides detailed dosing and fractionation recommendations on the basis of the size of the metastases. For patients with resected brain metastases, radiation therapy (SRS or whole-brain radiation therapy [WBRT]) is recommended to improve intracranial disease control; if there are limited additional brain metastases, SRS is recommended over WBRT. For patients with favorable prognosis and brain metastases ineligible for surgery and/or SRS, WBRT is recommended with hippocampal avoidance where possible and the addition of memantine is recommended. For patients with brain metastases, limiting the single-fraction V 12Gy to brain tissue to ≤ 10 cm 3 is conditionally recommended. Additional information is available at www.asco.org/neurooncology-guidelines .
Relation of Household Income to Access and Adherence to Combination Sacubitril/Valsartan in Heart Failure: A Retrospective Analysis of Commercially Insured Patients
Swabe, Gretchen , Addison, Daniel , Essien, Utibe R. , Breathett, Khadijah , Brewer, LaPrincess C. , Mazimba, Sula , Mohammed, Selma F. , Magnani, Jared W. , Johnson, Amber E , Swabe, Gretchen M , Addison, Daniel , Essien, Utibe R , Breathett, Khadijah , Brewer, LaPrincess C , Magnani, Jared W

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | May 13, 2022 | Volume: 15 | Issue: 7 | Pages: No page available

10.1161/circoutcomes.122.009179 | PMID 35549378 Get It

Background: Outcomes in heart failure with reduced ejection fraction (HFrEF) are influenced by access and adherence to guideline-directed medical therapy. Our objective was to study the association between annual household income and: (1) the odds of having a claim for sacubitril/valsartan among insured patients with HFrEF and (2) medication adherence (measured as the proportion of days covered). We hypothesized that lower annual household income is associated with decreased odds of having a claim for and adhering to sacubitril/valsartan. Methods: Using the Optum de-identified Clinformatics Data Mart, patients with HFrEF and ≥6 months of enrollment for follow-up (2016–2020) were included. Covariates included age, sex, race, ethnicity, educational attainment, US region, number of prescribed medications, and Elixhauser Comorbidity Index. Prescription for sacubitril/valsartan was defined by the presence of a claim within 6 months of HFrEF diagnosis. Adherence was defined as proportion of days covered ≥80%. We fit multivariable-adjusted logistic regression models and hierarchical logistic regression accounting for covariates. Results: Among 322 007 individuals with incident HFrEF, 135 282 had complete data for analysis. Of the patients eligible for sacubitril/valsartan, 4.7% (6372) had a claim within 6 months of HFrEF diagnosis. Following multivariable adjustment, individuals in the lowest annual income category (<$40 000) were significantly less likely (odds ratio, 0.83 [95% CI, 0.76–0.90]) to have a sacubitril/valsartan claim within 6 months of HFrEF diagnosis than those in the highest annual income category (≥$100 000). Annual income <$40 000 was associated with lower odds of proportion of days covered ≥80% compared with income ≥$100 000 (odds ratio, 0.70 [95% CI, 0.59–0.83]). Conclusions: Lower household income is associated with decreased likelihood of a sacubitril/valsartan claim and medication adherence within 6 months of HFrEF diagnosis, even after adjusting for sociodemographic and clinical factors. Future analyses are needed to identify additional social factors associated with delays in sacubitril/valsartan initiation and long-term adherence.
Predictive Modeling of New-Onset Postoperative Diplopia Following Orbital Decompression for Thyroid Eye Disease
Nair, Archana , Ediriwickrema, Lilangi S. , Dolman, Peter J. , Law, Geoffrey , Harrison, Andrew R. , Mokhtarzadeh, Ali , Stewart, Krista J., Men, Clara J. , Lucarelli, Mark J., Landingham, Suzanne van, Wingelaar, Maxwell , Verma, Rohan , Chen, Allison , Selva, Dinesh , Garrity, James, Eckel, Laurence J. , Kazim, Michael, Godfrey, Kyle J. , Korn, Bobby S. , Kikkawa, Don O. , Eckel, Laurence, Stewart, Krista, Landingham, Suzanne W. van , Baxter, Sally L.

Mayo Clinic

Ophthalmic Plastic & Reconstructive Surgery | May 13, 2022 | Volume: 38 | Issue: 6 | Pages: 551-557

10.1097/iop.0000000000002196 | PMID 35551414 Get It

Purpose: To identify risk factors for the development of new-onset, postoperative diplopia following orbital decompression surgery based on patient demographics, clinical exam characteristics, radiographic parameters, and surgical techniques. Methods: We conducted a multi-center retrospective chart review of patients who underwent orbital decompression for thyroid eye disease (TED). Patient demographics, including age, gender, smoking history, preoperative exophthalmometry, clinical activity score (CAS), use of peribulbar and/or systemic steroids, and type of orbital decompression were reviewed. Postoperative diplopia was determined at a minimum of 3 months postoperatively and before any further surgeries. Cross-sectional area ratios of each extraocular muscle to orbit and total fat to orbit were calculated from coronal imaging in a standard fashion. All measurements were carried out using PACS imaging software. Multivariable logistic regression modeling was performed using Stata 14.2 (StataCorp, College Station, TX). Results: A total of 331 patients without preoperative diplopia were identified. At 3 months postoperatively, 249 patients had no diplopia whereas 82 patients developed diplopia. The average postoperative follow-up was 22 months (range 3–156) months. Significant preoperative clinical risk factors for postoperative diplopia included older age at surgery, proptosis, use of peribulbar or systemic steroids, elevated clinical activity score, and presence of preoperative compressive optic neuropathy. Imaging findings of enlarged cross-sectional areas of each rectus muscle to the overall orbital area also conferred a significant risk of postoperative diplopia. Regarding surgical factors, postoperative diplopia was more common among those undergoing medial wall decompression, bilateral orbital surgery, and balanced decompression, whereas endoscopic medial wall decompression was found to be relatively protective. Conclusions: This study identifies risk factors associated with the development of diplopia following orbital decompression using multivariable data. This study demonstrates that several characteristics including age, clinical activity score, the cross-sectional muscle to orbit ratios, in addition to the type of orbital decompression surgery, are predictive factors for the development of new-onset postoperative diplopia.
Monoclonal and oligoclonal anti-platelet factor 4 antibodies mediate VITT
Kanack, Adam J. , Bayas, Antonios , George, Gemlyn , Singh, Bandana, Kohlhagen, Mindy , Splinter, Noah P., Christ, Monika , Naumann, Markus, Moser, Karen , Smock, Kristi J. , Grazioli, Alison , Wen, Renren , Wang, Demin , Murray, David , Padmanabhan, Anand , Abou-Ismail, Mouhamed Yazan , Kohlhagen, Mindy C, Smock, Kristi J , Wen, Renren , Murray, David L., Padmanabhan, Anand , Wang, Demin

Mayo Clinic

Blood | May 13, 2022 | Volume: 140 | Issue: 1 | Pages: 73-77

10.1182/blood.2021014588 | PMID 35560046 Get It

Kanack and colleagues analyze anti-platelet factor 4 antibodies from 5 patients with vaccine-induced thrombotic thrombocytopenia (VITT) secondary to COVID-19 adenoviral vaccination and antibodies from patients with spontaneous heparin-induced thrombocytopenia (HIT) and classical HIT. VITT antibodies are monoclonal or oligoclonal, similar to spontaneous HIT, whereas classical HIT antibodies are polyclonal. Heparin inhibits antibody-induced platelet activation in VITT, suggesting that heparin should be considered for the treatment of VITT.
Efficacy and Safety of Taliglucerase Alfa for the Treatment of Gaucher Disease: A 9-Year Experience
Paskulin, Livia , Starosta, Rodrigo Tzovenos , Krug, Bárbara , Picon, Paulo Dornelles , Schwartz, Ida Vanessa Döederlein , Schwartz, Ida Vanessa Doederlein , Vairo, Filippo Pinto e , Krug, Bárbara C.

Mayo Clinic

Journal of Inborn Errors of Metabolism and Screening | May 13, 2022 | Volume: 10 | Issue: No issue available | Pages: No page available

10.1590/2326-4594-jiems-2021-0031 Get It

U.S. Thyroid Cancer Incidence Fell but Mortality Climbing in Recent Years
Rahimi, Leili , Brito, Juan P.

Mayo Clinic

Clinical Thyroidology | May 13, 2022 | Volume: 34 | Issue: 5 | Pages: 213-215

10.1089/ct.2022;34.213-215 Get It

Cannabis and Cannabinoids in the Perioperative Period
Lee, Bradley H. , Sideris, Alexandra , Ladha, Karim S. , Johnson, Rebecca L. , Wu, Christopher L

Mayo Clinic

Anesthesia & Analgesia | May 13, 2022 | Volume: 138 | Issue: 1 | Pages: 16-30

10.1213/ane.0000000000006070 | PMID 35551150 Get It

Cannabis use is increasingly common, and with a growing number of jurisdictions implementing legalization frameworks, it is likely that providers will encounter more patients who use cannabis. Therefore, it is important for providers to understand the implications of cannabis use and practical considerations for the perioperative period. Cannabis affects multiple organ systems and may influence intraoperative anesthesia, as well as postoperative pain management. The effects of cannabis and key anesthetic considerations are reviewed here.
Observational data from the adalimumab post‐marketing PYRAMID registry of patients with Crohn's disease who became pregnant: A post hoc analysis
Hart, Ailsa , D’Haens, Geert , Bereswill, Mareike, Finney‐Hayward, Tricia , Kalabic, Jasmina , Levy, Gweneth, Liang, Huifang , Seow, Cynthia H. , Loftus, Edward V. , Reinisch, Walter, Satsangi, Jack , Loftus, Edward V , Panaccione, Remo , Reinisch, Walter

Mayo Clinic

United European Gastroenterology Journal | May 13, 2022 | Volume: 10 | Issue: 5 | Pages: 485-495

10.1002/ueg2.12236 | PMID 35560533 Get It

AbstractBackgroundPYRAMID was an international post‐marketing registry that aimed to collect data on the long‐term safety and effectiveness of adalimumab treatment per local standard of care in patients with moderately to severely active Crohn's disease (CD). Here, we present post hoc analyses of observational data from patients who became pregnant while participating in this registry and receiving adalimumab.MethodsFrom the subpopulation of patients receiving adalimumab who became pregnant while taking part in PYRAMID, data on patient characteristics, pregnancy outcomes, and complications of pregnancy were analysed retrospectively.ResultsAcross the PYRAMID registry, 293 pregnancies occurred in patients who had gestational adalimumab exposure (average disease duration at last menstrual period: 8.6 years), resulting in 300 pregnancy outcomes. A total of 197 pregnancies (67.2%) were exposed to adalimumab in all trimesters per physician's decision. Of the known reported outcomes (96.3%), 81.7% (236/289) were live births, 10.4% (30/289) were spontaneous abortions, 4.8% (14/289) elective terminations, 2.8% (8/289) ectopic pregnancies, and 0.3% (1/289) was a stillbirth. Congenital malformations (pulmonary valve stenosis and tricuspid valve incompetence) were reported in one infant. In addition to the pregnancy outcomes described above, 23 complications of pregnancy were reported in 20 patients.ConclusionsThis analysis showed that adalimumab treatment in patients with CD, who became pregnant whilst participating in the PYRAMID registry, contributed no additional adverse effects during the pregnancy course or on pregnancy outcomes.
Two-Dimensional Ti3C2 MXene-Based Novel Nanocomposites for Breath Sensors for Early Detection of Diabetes Mellitus
Rudie, Anna, Schornack, Anna Marie R , Wu, Qiang , Zhang, Qifeng, Wang, Danling , Schornack, Anna Marie , Zhang, Qifeng

Mayo Clinic

Biosensors | May 13, 2022 | Volume: 12 | Issue: 5 | Pages: 332

10.3390/bios12050332 | PMID 35624633 Get It

The rates of diabetes throughout the world are rising rapidly, impacting nearly every country. New research is focused on better ways to monitor and treat this disease. Breath acetone levels have been defined as a biomarker for diabetes. The development of a method to monitor and diagnose diabetes utilizing breath acetone levels would provide a fast, easy, and non-invasive treatment option. An ideal material for point-of-care diabetes management would need to have a high response to acetone, high acetone selectivity, low interference from humidity, and be able to operate at room temperature. Chemiresistive gas sensors are a promising method for sensing breath acetone due to their simple fabrication and easy operation. Certain semiconductor materials in chemiresistive sensors can react to acetone in the air and produce changes in resistance that can be correlated with acetone levels. While these materials have been developed and show strong responses to acetone with good selectivity, most of them must operate at high temperatures (compared to RT), causing high power consumption, unstable device operation, and complex device design. In this paper, we systematically studied a series of 2-dimensional MXene-based nanocomposites as the sensing materials in chemiresistive sensors to detect 2.86 ppm of acetone at room temperature. Most of them showed great sensitivity and selectivity for acetone. In particular, the 1D/2D CrWO/Ti3C2 nanocomposite showed the best sensing response to acetone: nine times higher sensitivity than 1D KWO nanowires. To determine the sensing selectivity, a CrWO/Ti3C2 nanocomposite-based sensor was exposed to various common vapors in human breath. The result revealed that it has excellent selectivity for acetone, and far lower responses to other vapors. All these preliminary results indicate that this material is a promising candidate for the creation of a point-of-care diabetes management device.
Faculty Opinions recommendation of Classifying esophageal motility by FLIP panometry: A study of 722 subjects with manometry.
Ravi, Karthik

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | May 13, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.741024238.793592920 Get It